door Thijs » zo 05 nov 2023, 13:56
Ook in Amerika heeft de internationale hyperhidrosis vereniging een bericht uit doen gaan over axhidrox:
Topical Glycopyrronium Bromide Cream Treatment Approved in 12 European Countries
In 2022 and 2023 a topical (i.e. applied on top of the skin) cream for underarm hyperhidrosis was approved by European medical governing bodies for use in the following 12 European countries: Italy, Denmark, Latvia, Austria, Sweden, Estonia, Finland, Croatia, Germany, The Netherlands, Norway, and Lithuania.
The treatment is a 1% glycopyrronium bromide-based cream (from the Dr. Wolff Group) to be applied to the affected area twice a week. Glycopyrronium bromide (GPB) is an anticholinergic often used to treat excessive salivation or respiratory secretions, and can be used as an oral treatment for excessive sweating. Glycopyrronium bromide blocks the action of acetylcholine at muscarinic acetylcholine receptors, which are responsible for sweat gland activation, among other things.
According to studies, after eight days of use the cream was able to reduce sweat production so that 60% of treated patients said that their lives were “changed for the better.” Side effects were found to be mild or moderate, temporary, and did not lead to discontinuation of the product; as an example - 9.2% of patients had mild or moderate application site reactions. The most commonly reported side effect was dry mouth (occuring in 16.1% of users).
In related research looking at the use of the 1% GPB cream once daily in patients with moderate or severe primary axillary hyperhidrosis, 57% of the patients had their sweating cut in half using the GPB cream (compared to 34% using the placebo).
A company called Therapeutics, Inc. says it will also conduct a study comparing the safety, tolerability, and efficacy of 1% Glycopyrronium Bromide (GPB) cream (the Dr. Wolff Group product) with that of Qbrexza® (Glycopyrronium) Cloth 2.4% for the treatment of primary axillary hyperhidrosis. The study is not yet recruiting participants.
Bron:
https://www.sweathelp.org/hyperhidrosis ... pment.htmlOok in Amerika heeft de internationale hyperhidrosis vereniging een bericht uit doen gaan over axhidrox:
Topical Glycopyrronium Bromide Cream Treatment Approved in 12 European Countries
In 2022 and 2023 a topical (i.e. applied on top of the skin) cream for underarm hyperhidrosis was approved by European medical governing bodies for use in the following 12 European countries: Italy, Denmark, Latvia, Austria, Sweden, Estonia, Finland, Croatia, Germany, The Netherlands, Norway, and Lithuania.
The treatment is a 1% glycopyrronium bromide-based cream (from the Dr. Wolff Group) to be applied to the affected area twice a week. Glycopyrronium bromide (GPB) is an anticholinergic often used to treat excessive salivation or respiratory secretions, and can be used as an oral treatment for excessive sweating. Glycopyrronium bromide blocks the action of acetylcholine at muscarinic acetylcholine receptors, which are responsible for sweat gland activation, among other things.
According to studies, after eight days of use the cream was able to reduce sweat production so that 60% of treated patients said that their lives were “changed for the better.” Side effects were found to be mild or moderate, temporary, and did not lead to discontinuation of the product; as an example - 9.2% of patients had mild or moderate application site reactions. The most commonly reported side effect was dry mouth (occuring in 16.1% of users).
In related research looking at the use of the 1% GPB cream once daily in patients with moderate or severe primary axillary hyperhidrosis, 57% of the patients had their sweating cut in half using the GPB cream (compared to 34% using the placebo).
A company called Therapeutics, Inc. says it will also conduct a study comparing the safety, tolerability, and efficacy of 1% Glycopyrronium Bromide (GPB) cream (the Dr. Wolff Group product) with that of Qbrexza® (Glycopyrronium) Cloth 2.4% for the treatment of primary axillary hyperhidrosis. The study is not yet recruiting participants.
Bron: https://www.sweathelp.org/hyperhidrosis-treatments/treatments-in-development.html
